Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Liquidia is poised for success due to its innovative approach to addressing unmet patient needs, with a current focus on pulmonary hypertension. The company's proprietary PRINT technology allows for precise and uniform production of drug particles, giving it a competitive advantage in the biopharmaceutical industry. With a successful launch of its product YUTREPIA, strong revenue growth, and continued positive uptake, Liquidia is expected to achieve its target of over $1 billion in net revenue by 2027. While there are inherent risks in the biopharmaceutical market, including competition and potential financial needs, these are mitigated by the company's strong market position, increased prescribing breadth and depth, and positive sentiment from key opinion leaders. The recent Supreme Court ruling in the Amarin v. Hikma case, and its potential impact on the ongoing legal battle with United Therapeutics, could further solidify the company's position in the market. Overall, the positive trajectory of Liquidia's business and its potential for continued success make it a strong investment opportunity.

Bears say

Liquidia is facing multiple challenges, with the pending legal decision being the key overhang, which could significantly impact the company's position in the inhaled prostacyclin market. The recent Amarin v. Hikma ruling shows the potential for a severe outcome for Liquidia in the ongoing legal battle. Furthermore, the company faces competition from established players, such as United Therapeutics, and may require additional financing to complete its drug development.

LQDA has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 8 analysts, LQDA has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $89.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $89.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.